CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Month: May 2023
Goodness Growth Holdings Closes on Initial $2.0 Million Tranche of $10.0 Million Financing Commitment
MINNEAPOLIS, May 01, 2023 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF),...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional...
Nanox Files 2022 Annual Report on Form 20-F
NEVE ILAN, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical...
Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing
MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a...
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused...
Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the...
Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy
McNulty brings deep experience in capital formation and business development to Ring Follows recent appointment of Dr. Christopher Wright as...
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit
Dr. Newman also to give two presentations on the Company’s Decoy platform at the event to be held in Boston...
Final Sanction Removed at InnovAge Sacramento PACE Center Enabling New Participant Enrollment
DENVER, May 01, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare...
Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has...
Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023
RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing...
ODAIA Raises $25 Million in Series B Funding to Advance Its AI-Driven Commercial Insights Software for Pharma
With funding, ODAIA to fuel expansion and support the rapid growth of its AI-powered solutions that help pharma companies put...
Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights
Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two...
The Canadian Dermatology Association launches its month-long National Sun Awareness Campaign, and its partnership and support of Melanoma Canada’s Mole Mobile Skin Cancer Screening Unit
OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) launches its month-long Sun Awareness Month campaign, urging...
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group,...
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S....
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients...